lurasidone

Catalog No.S5714 Synonyms: SM-13496

For research use only.

Lurasidone (SM-13496) is a second-generation antipsychotic agent that exhibits full antagonism at dopamine D2 and serotonin 5-HT2A receptors with binding affinities Ki = 1 nM and Ki = 0.5 nM, respectively. It also has high affinity for serotonin 5-HT7 receptors (Ki = 0.5 nM), partial agonist activity at 5-HT1A receptors (Ki = 6.4 nM) and lacks affinity for histamine H1 and muscarinic M1 receptors.

lurasidone Chemical Structure

CAS No. 367514-87-2

Purity & Quality Control

Choose Selective Dopamine Receptor Inhibitors

Other Dopamine Receptor Products

Biological Activity

Description Lurasidone (SM-13496) is a second-generation antipsychotic agent that exhibits full antagonism at dopamine D2 and serotonin 5-HT2A receptors with binding affinities Ki = 1 nM and Ki = 0.5 nM, respectively. It also has high affinity for serotonin 5-HT7 receptors (Ki = 0.5 nM), partial agonist activity at 5-HT1A receptors (Ki = 6.4 nM) and lacks affinity for histamine H1 and muscarinic M1 receptors.
Targets
5-HT2A [1]
(Cell-free assay)
5-HT7 receptor [1]
(Cell-free assay)
D2 receptor [1]
(Cell-free assay)
5-HT1A receptor [1]
(Cell-free assay)
0.5 nM(Ki) 0.5 nM(Ki) 1 nM(Ki) 6.4 nM(Ki)
In vitro

Lurasidone is a new atypical antipsychotic in the benzoisothiazoles class of chemicals. Like most second-generation antipsychotics it is a full antagonist at dopamine D2 and serotonin 5-HT2A receptors, and is a partial agonist at 5-HT1A receptors. It has much greater affinity for 5-HT7 subtype receptors than other atypical antipsychotics. Lurasidone also has high affinity for the 5-HT1A subtype, α2c-adrenergic receptors and low affinity for α1-adrenergic receptors. It has minimal affinity for 5-HT2C receptors and negligible affinity for histamine H1 and muscarinic receptors[2].

In vivo Lurasidone is rapidly absorbed, reaching peak concentrations within 1.5–3 hours (tmax) after single and multiple oral doses. Once absorbed, it extensively distributes in tissues and rapidly enters the CNS. Lurasidone has high binding to human plasma albumin and alpha-1-glycoprotein (≥99%)[2]. Long-term treatment of schizophrenia with lurasidone has been shown to reduce the risk of relapse. The elimination half-life of lurasidone is about 20-40 h. Mean Cmax and area under the curve (AUC) for lurasidone were approximately threefold and twofold greater, respectively, in a comparison of administration with food v. fasting. Lurasidone absorption is independent of food fat content. Lurasidone is metabolised primarily via CYP3A4[1]. In animal studies, lurasidone penetrated the placental barrier and distributed into the fetus, and was excreted in milk during lactation[2].

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 7 mg/mL
(14.2 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 492.68
Formula

C28H36N4O2S

CAS No. 367514-87-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CCC(C(C1)CN2CCN(CC2)C3=NSC4=CC=CC=C43)CN5C(=O)C6C7CCC(C7)C6C5=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03627195 Completed Drug: DSP-1349M|Drug: placebo Schizophrenia Sunovion June 7 2018 Phase 1
NCT02731612 Recruiting Drug: lurasidone|Other: Placebo Bipolar Disorder Nazlin Walji|University of British Columbia May 8 2017 Phase 3
NCT02147379 Completed Drug: Lurasidone Bipolar I Disorder University of British Columbia May 2014 Phase 3
NCT02174523 Completed Drug: 40mg lurasidone|Drug: placebo Schizophrenia Sumitomo Pharmaceutical (Suzhou) Co. Ltd.|Xuhui Central Hospital Shanghai April 2014 Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy lurasidone | lurasidone ic50 | lurasidone price | lurasidone cost | lurasidone solubility dmso | lurasidone purchase | lurasidone manufacturer | lurasidone research buy | lurasidone order | lurasidone mouse | lurasidone chemical structure | lurasidone mw | lurasidone molecular weight | lurasidone datasheet | lurasidone supplier | lurasidone in vitro | lurasidone cell line | lurasidone concentration | lurasidone nmr